Semaglutide and Heart Risk in HIV

On 17 September 2026, a research team led by J. Daher published a 32-week randomized controlled trial in the journal AIDS, testing whether semaglutide, the GLP-1 receptor agonist sold as Ozempic and Wegovy, could improve markers of heart disease risk in adults living with HIV. The trial enrolled 108 virologically suppressed adults with HIV-associated lipohypertrophy, a pattern of fat redistribution, mostly extra fat around the abdomen and organs, that can appear after years on antiretroviral therapy, the daily medicines that keep HIV suppressed. Two numbers anchor the result. Participants assigned to semaglutide saw their calculated 10-year risk of atherosclerotic cardiovascular disease, or ASCVD, fall 32.6 percent more than placebo (P = 0.026). A blood marker of inflammation called hsCRP, short for high-sensitivity C-reactive protein, dropped 23.4 percent more than placebo (P = 0.02)^[1].

What the trial actually measured

The researchers tracked several measures of subclinical cardiovascular health: damage or risk that a scan or a blood test can catch well before it turns into a heart attack or a stroke. That included arterial stiffness by pulse wave velocity, which times how fast a pressure wave travels along the arteries and stands in for how rigid the vessel walls have become. A cardiac CT scan supplied the coronary artery calcium score, a count of calcium deposits inside the heart's own arteries. The trial also tracked resting energy expenditure, the number of calories the body burns at rest, alongside a metabolic panel that included hsCRP and the calculated ASCVD risk score^[1].

Two of those measures moved. The calculated ASCVD risk score and hsCRP both improved by a statistically significant margin over the 32 weeks. Pulse wave velocity, the coronary artery calcium score, and resting energy expenditure showed no significant difference between the semaglutide group and the placebo group^[1]. The trial authors framed the result as an improvement in overall cardiometabolic health, while stopping short of claiming a vascular or structural change.

Why cardiovascular risk in HIV needed its own trial

People with HIV carry a heavier cardiovascular disease burden than the general population, and the reasons stack on top of each other. HIV infection itself appears to raise cardiovascular risk beyond standard factors like smoking and blood pressure. A review of the evidence found that men with long-lasting HIV infection had a higher prevalence and a greater degree of coronary atherosclerosis on imaging than HIV-negative men, even without symptoms^[2]. Chronic, low-grade inflammation runs through much of that excess risk. In the same review, a third of people on long-term antiretroviral therapy carried hsCRP levels above 3 mg/L, a threshold linked to elevated cardiovascular risk in the general population^[2].

Antiretroviral therapy carries its own trade-off. Older protease inhibitors have been linked to a measurable rise in heart-attack risk with each additional year of use, an effect that shrank but did not disappear once researchers adjusted for cholesterol levels^[2]. Weight gain and lipohypertrophy sit on top of that risk. Viral suppression achieved, but a body carrying more visceral fat and more background inflammation than before treatment started, is the population the new trial set out to study^[1].

Surrogate markers are not the same as proven outcomes

It matters that this trial measured surrogate markers: calculated risk scores and imaging results that predict cardiovascular disease without being the disease itself. The stronger kind of evidence comes from a trial that counts actual cardiovascular events in a group large enough to detect a real difference. Semaglutide already has that kind of evidence, in a different population. The SELECT trial randomized 17,604 adults with obesity and established cardiovascular disease, but no diabetes, to semaglutide or placebo and followed them for a median of roughly 40 months. A primary cardiovascular event occurred in 6.5 percent of the semaglutide group against 8.0 percent on placebo, a 20 percent relative reduction, with a hazard ratio of 0.80^[3]. No trial of that size has tested semaglutide's effect on hard cardiovascular outcomes specifically in people with HIV.

A trial does exist that shows what a hard-outcomes result looks like in the HIV population itself, and it did not involve semaglutide. REPRIEVE randomized 7,769 adults with HIV and low-to-moderate cardiovascular risk to daily pitavastatin or placebo and followed them for a median of 5.1 years. Major cardiovascular events occurred at a rate of 4.81 per 1,000 person-years on pitavastatin against 7.32 per 1,000 person-years on placebo, a hazard ratio of 0.65, and the trial stopped early because the benefit was already clear^[4]. Semaglutide has not yet been tested against that bar in HIV. The September 2026 result is an early, encouraging surrogate-marker finding in a small group over a comparatively short window, not a demonstration that semaglutide prevents heart attacks or strokes in people with HIV.

What the trial does not show

108 participants over 32 weeks is a modest sample for a chronic-disease question. Two of the measured outcomes, pulse wave velocity and coronary calcium, showed no significant change, and coronary calcium in particular tends to move slowly no matter the treatment, so 32 weeks may simply be too short a window to see it shift. The trial authors called for larger, longer studies before drawing conclusions about durable cardiovascular benefit^[1]. Semaglutide is not approved by the FDA for HIV-associated lipohypertrophy or for cardiovascular-risk reduction specifically in people with HIV. In the United States, semaglutide is approved for type 2 diabetes and for chronic weight management, a narrower and different set of indications.

What this means for readers on antiretroviral therapy

If you are living with HIV and considering semaglutide for weight or metabolic reasons, this trial adds evidence that the drug can move some cardiovascular risk markers in that specific setting, alongside evidence that it does not yet move others. It is not evidence that semaglutide prevents heart attacks or strokes in people with HIV, and it is not a basis for starting or adjusting any medicine on your own. That conversation belongs with an HIV specialist or a cardiologist who can weigh your antiretroviral regimen, your existing cardiovascular risk factors, and whether semaglutide's approved uses apply to your situation.

None of the above is medical advice, and none of it is a recommendation to start, stop, or change any medicine. Any decision about semaglutide or any other prescription drug belongs with a clinician who knows your history.